Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01290549
What this trial is testing

Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

Who this might be right for
Non-Hodgkins LymphomaChronic Lymphocytic Leukemia
Genentech, Inc. 95
Testing effectiveness (Phase 2)UnknownNCT00014664
What this trial is testing

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
PDL BioPharma, Inc.
Testing effectiveness (Phase 2)Active Not RecruitingNCT04416984
What this trial is testing

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Who this might be right for
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Allogene Therapeutics 160
Testing effectiveness (Phase 2)Ended earlyNCT04082936
What this trial is testing

Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin LymphomaFollicular LymphomaDLBCL+2 more
IGM Biosciences, Inc. 97
Testing effectiveness (Phase 2)WithdrawnNCT05365100
What this trial is testing

BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL

Who this might be right for
CLL/SLLNHL
BioNova Pharmaceuticals (Shanghai) LTD.
Large-scale testing (Phase 3)WithdrawnNCT00551239
What this trial is testing

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
LeukemiaLymphoma
CTI BioPharma
Very early researchUnknownNCT04639739
What this trial is testing

Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma.

Who this might be right for
NHL
Xinqiao Hospital of Chongqing 9
Testing effectiveness (Phase 2)Looking for participantsNCT05554939
What this trial is testing

Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL

Who this might be right for
Non Hodgkin's Lymphoma
Chinese PLA General Hospital 30
Early research (Phase 1)UnknownNCT04296461
What this trial is testing

Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma

Who this might be right for
B-cell Non-Hodgkin Lymphoma
UWELL Biopharma 20
Large-scale testing (Phase 3)Ended earlyNCT02951156
What this trial is testing

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Pfizer 29
Not applicableStudy completedNCT00053157
What this trial is testing

Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+3 more
Roswell Park Cancer Institute 10
Large-scale testing (Phase 3)Study completedNCT04833114
What this trial is testing

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Relapsed Diffuse Large B-cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
GWT-TUD GmbH 306
Early research (Phase 1)Looking for participantsNCT06191887
What this trial is testing

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Who this might be right for
B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+12 more
Mayo Clinic 27
Early research (Phase 1)Active Not RecruitingNCT03853616
What this trial is testing

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

Who this might be right for
Acute Lymphoblastic Leukemia RecurrentB-cell Lymphoma RecurrentB-cell Lymphoma Refractory+2 more
Miltenyi Biomedicine GmbH 48
Testing effectiveness (Phase 2)Study completedNCT02199184
What this trial is testing

Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Who this might be right for
AIDS-Related Burkitt LymphomaAtypical Burkitt/Burkitt-Like LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements+5 more
M.D. Anderson Cancer Center 14
Testing effectiveness (Phase 2)Study completedNCT01556035
What this trial is testing

Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma

Who this might be right for
Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)
University Hospital, Bordeaux 19
Testing effectiveness (Phase 2)Ended earlyNCT00079443
What this trial is testing

FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Small Lymphocytic Lymphoma
National Cancer Institute (NCI) 60
Early research (Phase 1)Study completedNCT02741388
What this trial is testing

A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP

Who this might be right for
B-cell Lymphoma
The Lymphoma Academic Research Organisation 39
Testing effectiveness (Phase 2)Looking for participantsNCT05643742
What this trial is testing

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
B-cell LymphomaNon-Hodgkin LymphomaB-cell Malignancy+5 more
CRISPR Therapeutics AG 120
Testing effectiveness (Phase 2)Study completedNCT03994913
What this trial is testing

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

Who this might be right for
Refractory B-Cell Non-Hodgkin LymphomaRelapsed B-cell Non-Hodgkin Lymphoma
CARsgen Therapeutics Co., Ltd. 20
Next Page